Mayo Clinic
Rochester, Minnesota, 55905, United States
NCT Number: NCT00414180
To determine the efficacy and safety of bupropion SR for quitting tobacco in smokeless tobacco users.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Rochester, Minnesota, 55905, United States
CONTEXT: No pharmacotherapies have been shown to increase long-term (≥ 6 month) tobacco abstinence rates among smokeless tobacco (ST) users, although bupropion SR has demonstrated potential efficacy in pilot studies.
OBJECTIVE: To determine the efficacy and safety of bupropion SR for tobacco abstinence among ST users compared with placebo.
DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled trial conducted between August 2003 to May 2005 at two research centers with a 12-week treatment period and follow-up of smoking status to week 52.
INTERVENTION: Bupropion SR titrated to 150 mg twice daily or placebo for 12 weeks plus weekly behavioral interventions.
Main Outcome Measures: The primary endpoint was 7-day point-prevalence tobacco abstinence rate at week 12. Secondary outcomes included the prolonged and continuous tobacco abstinence rates at weeks 12, 24, and 52.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Mayo Clinic
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00265681
Behavior, Health Behavior
Bloomington, Minnesota, United States
View Trial DetailsNCT01369693
Behavior, Harm Reduction
Helsingborg, Sweden
View Trial DetailsNCT01249339
Behavior, Harm Reduction
Helsingborg, Sweden
View Trial DetailsNCT07107139
Behavior, Smokeless Tobacco
Buffalo, New York, United States
View Trial Details